Watch GYRE. Know when insiders buy.
One email the day a filing lands. Free.
GYRE
GYRE THERAPEUTICS, INC.
6.70
+0.01 +0.15%
USD · close Sep 16
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
55
WATCH · shorts 55
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $747.1MP/E —DIV YIELD —FCF YIELD -0.82%REV TTM $119.4M +13.5%NET INCOME −$28.2M −558.6%NET CASH $43.3M52W 5.56 – 8.87SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $29.1M | −2.1% | 92.4% | −$14.4M | −$14.3M | — | -0.12 | −$16.7M | $262K | −$17M | Aug 7 |
| Q1 2026 · Mar 31 | $22.5M | +2.1% | 94.6% | −$9.4M | −$18.6M | −476.2% | -0.10 | $3.2M | $178K | $3M | Aug 7 |
| Q4 2025 · Dec 31derived | $37.2M | +33.4% | 95.3% | $118K | −$1.3M | −320.7% | -0.02 | −$5.6M | $144K | −$5.8M | Mar 13 |
| Q3 2025 · Sep 30 | $30.6M | +19.9% | 94.7% | $6.9M | $5.9M | +107.8% | 0.03 | $14.2M | $589K | $13.6M | Nov 7 |
| Q2 2025 · Jun 30 | $29.7M | +17.9% | 86.2% | −$2.2M | −$2.2M | −149.3% | -0.03 | −$7.5M | $335K | −$7.8M | Aug 7 |
| Q1 2025 · Mar 31 | $22.1M | −18.8% | 95.9% | $2.3M | $4.9M | −50.3% | 0.00 | −$129K | $122K | −$251K | Aug 7 |
| Q4 2024 · Dec 31derived | $27.9M | +2.7% | 95.8% | $665K | $598K | — | 0.00 | −$2.8M | −$65K | −$2.7M | Mar 13 |
| Q3 2024 · Sep 30 | $25.5M | −20.5% | 96.2% | $4.2M | $2.9M | −62.0% | 0.01 | $1.7M | $693K | $1M | Nov 7 |
| Q2 2024 · Jun 30 | $25.2M | — | 96.9% | $3.2M | $4.5M | — | 0.01 | −$5.5M | $1.5M | −$6.9M | Nov 7 |
| Q1 2024 · Mar 31 | $27.2M | — | 96.4% | $8.1M | $9.9M | — | 0.03 | $2.9M | $231K | $2.7M | Nov 7 |
| Q4 2023 · Dec 31derived | $27.1M | — | 95.4% | −$91.6M | −$81.7M | — | -1.51 | $3.4M | $2.3M | $1M | Mar 17 |
| Q3 2023 · Sep 30 | $32M | — | 96.3% | $12.8M | $7.5M | — | 0.05 | $7.6M | $2M | $5.6M | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $116.6M | 95.4% | $11.5M | $9.9M | 8.5% | 0.02 | $1M | $1.2M | −$180K | — | — |
| FY2024 · to Dec 31 | $105.8M | 96.3% | $16.2M | $17.9M | 16.9% | 0.05 | −$3.6M | $2.3M | −$6M | — | — |
| FY2023 · to Dec 31 | $113.5M | 95.9% | −$67.2M | −$85.5M | -75.3% | -1.41 | $25.9M | $8.5M | $17.4M | — | — |
| FY2022 · to Dec 31 | $102.3M | 95.3% | $9.2M | $4.3M | 4.2% | 0.03 | $10.7M | $5M | $5.7M | — | $45M |
| FY2021 · to Dec 31 | $7.3M | — | −$87.9M | −$87.9M | -1198.3% | -2.87 | −$83.8M | $839K | −$84.6M | — | — |
| FY2020 · to Dec 31 | $20.9M | — | −$57.4M | −$56.2M | -268.5% | -2.93 | −$55M | — | — | — | — |
Every number comes from GYRE THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.